Business Context and Reporting Period
Company: Crinetics Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 27, 2026
Reporting Period: The filing addresses events occurring on February 27, 2026, regarding the change of the company's independent registered public accounting firm.
Key Financial Metrics
This filing does not contain financial performance data. The document focuses exclusively on corporate governance regarding the audit firm. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this specific report.
Material Changes
- Dismissal of Auditor: The Audit Committee approved the dismissal of BDO USA, P.C. as the independent registered public accounting firm effective February 27, 2026.
- Appointment of New Auditor: The Audit Committee approved the appointment of PricewaterhouseCoopers LLP (PwC) as the new independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Audit History: BDO's reports for fiscal years 2024 and 2025 were unqualified and contained no adverse opinions or disclaimers.
Management Commentary, Risks, and Contingencies
Disagreements and Reportable Events: The Company stated there were no disagreements with BDO regarding accounting principles, financial statement disclosures, or auditing scope/procedures during the 2024 and 2025 audits or the interim period through February 27, 2026. Additionally, no "reportable events" occurred as defined by Regulation S-K.
Consultations with New Auditor: The Company confirmed it did not consult with PwC regarding accounting principles, specified transactions, or potential audit opinions during the relevant periods prior to their appointment.
Exhibits: A letter from BDO USA, P.C. dated March 3, 2026, confirming their agreement with the Company's statements, is attached as Exhibit 16.1.
Investor Verification Checklist
- Verify the effective date of the transition from BDO to PwC (February 27, 2026).
- Review the attached letter from BDO (Exhibit 16.1) to confirm their concurrence with the Company's statements regarding the lack of disagreements.
- Monitor future filings (e.g., 10-K or 10-Q) for the first financial statements audited by PwC to assess any changes in audit scope or findings.
- Confirm that no undisclosed "reportable events" have emerged since the filing date.